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Abstract 
Three new ruthenium(II)-arene complexes, namely [(η6-p-cymene)Ru(Me2dppz)Cl]PF6 
(1), [(η6-benzene)Ru(Me2dppz)Cl]PF6 (2) and [(η
6
-p-cymene)Ru(aip)Cl]PF6 (3) (Me2dppz = 
11,12-dimethyldipyrido[3,2-a:2',3'-c]phenazine; aip = 2-(9-anthryl)-1H-imidazo[4,5-f][1,10] 
phenanthroline) have been synthesized and characterized using different spectroscopic 
techniques including elemental analysis. The complexes were found to be well soluble and stable 
in DMSO. The biological activity of the three complexes was tested in three different human 
cancer cell lines (A549, MDA-MB-231 and HeLa) and in one human non-cancerous cell line 
(MRC-5). Complexes 1 and 3, carrying η6-p-cymene as the arene ligand, were shown to be toxic 
in all cell lines in the low micromolar/subnanomolar range, with complex 1 being the most 
cytotoxic complex of the series. Flow cytometry analysis revealed that complex 1 caused 
concentration- and time-dependent arrest of the cell cycle in G2-M and S phase in HeLa cells. 
This event is followed by the accumulation of the sub-G1 DNA content after 48 h, in levels 
higher than cisplatin and in the absence of phosphatidylserine externalization. Fluorescent 
microscopy and acridine orange/ethidium bromide staining revealed that complex 1 induced both 
apoptotic and necrotic cell morphology characteristics. Drug-accumulation and DNA-binding 
studies performed by inductively coupled plasma mass spectrometry in HeLa cells showed that 
the total ruthenium uptake increased in a time- and concentration-dependent manner, and that 
complex 1 accumulated more efficiently than cisplatin at equimolar concentrations. The 
introduction of a Me2dppz ligand into the ruthenium(II)-p-cymene scaffold was found to allow 
for the discovery of a strongly cytotoxic complex with significantly higher cellular uptake and 
DNA-binding properties than cisplatin. 
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1. Introduction 
The majority of the anticancer chemotherapeutic treatments are based on platinum 
complexes (i.e. CDDP = cis-diamminedichloridoplatinum(II) better known as cisplatin, 
carboplatin and oxaliplatin) [
1
]. However, the use of these drugs is limited by their toxicity and 
acquired drug resistance [
2
]. These facts have initiated intensive research towards the discovery 
of novel metal-based drug candidates with better selectivity toward cancer cells [
3
, 
4
, 
5
, 
6
]. 
Among the different metals investigated for this purpose, ruthenium complexes have shown the 
greatest potential [
7
, 
8
]. For example, three Ru(III) complexes NAMI-A (trans-[tetrachlorido(1H-
imidazole)(S-dimethyl sulfoxide) ruthenate(III)]), KP1019 (indazolium trans-
[tetrachloridobis(1H-indazole) ruthenate(III)]), and KP1339 (sodium trans-[tetrachloridobis(1H-
indazole)ruthenate(III)]) have entered human clinical trials [
9
, 
10
, 
11
, 
12
, 
13
, 
14
]. Two of them, 
namely NAMI-A and KP1339 are now in phase II clinical trial [
15
]. In addition, two Ru(II) 
complexes, namely RAPTA-C ([Ru(η6-p-cymene)Cl2(pta)]; pta = 1,3,5-triaza-7-
phosphaadamantane)  and  TLD-1433 (as a photosensitizer in photodynamic therapy) should 
enter into clinical trials in the very near future [
16
, 
17
 ,
18
].  
Despite these promising results with ruthenium compounds, the quest for novel lead structures is 
still a topic of high interest. Of particular interest are arene ruthenium complexes with σ-bonded 
aromatic ligands that can bind to DNA both by metal coordination or through intercalation of an 
attached aromatic ligand [
19
, 
20
, 
21
]. Such a concept was employed by Sadler and co-workers, 
who reported DNA intercalation of [(arene)Ru(en)Cl]
+
 complexes where en is ethylenediamine 
and the arene ligands are biphenyl, 9,10-dihydroanthracene or 5,8,9,10-tetrahydroanthracene 
(Figure 1. a-c) [
22
]. Comparative analysis of Ru(II)-arene complexes containing 
tetrahydroanthracene (partial intercalation) or containing p-cymene (no intercalation) suggested 
that the complexes with an intercalating ligand have a stronger DNA mismatch repair protein 
inhibition [
23
] than the one which do not intercalate. In addition, it was found that the 
coordination of guanine to ruthenium may assist in the intercalation of the bulky 
tetrahydroanthracene ligand into DNA [
24
, 
25
, 
26
]. Of note, ruthenium(II)-benzene or 
ruthenium(II)-cymene derivatives coordinated to aryl imidazole and aryl benzimidazole were 
found to interact with DNA through binding and intercalation [
27
]. DFT calculation confirmed 
that large and flexible arene ligands are able to form more stabilizing intercalation interactions 
with DNA bases than small and less flexible arene ligands [
28
]. This concept was used in the 
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design of (arene)ruthenium(II) complexes of 1,3-dimethyl-4-acylpyrazolon-5-ato ligands where 
the arene is a monoaromatic ligand [
29
]. Docking studies of those complexes confirmed that 
increased aromaticity of the ligand is important for intercalation and π-π stacking interactions 
between the ligand and DNA base pairs (Figure 1. d). Worthy of note, Sheldrick et al. correlated 
the aromatic ring size with the cytotoxic properties of the resulting complexes (η6-
hexamethylbenzene)Ru(κ2N-N)](CF3SO3), where N-N = phen (1,10-phenanthroline), tap 
(1,4,5,8-tetraazaphenanthrene), dpq (dipyridoquinoxaline = pyrazino[2,3-
f][1,10]phenanthroline), dppz = dipyridophenazine, dppn = 4,5,9,16-tetraaza-
dibenzo[a,c]naphthacene (Figure 1. e) [
30
, 
31
]. The authors observed that the cytotoxicity of the 
complexes was increasing with the size of the intercalating moiety. The same trend was observed 
in the case of [Ru(bpy)2(N-N)]Cl2 complexes when the N-N ligands bpy, phen, dpq, dppz and 
dppn were compared [
32
]. Also, a Ru(II)-benzene complex with a phenanthroimidazole 
derivative as the intercalative moiety was shown to damage DNA by intercalation in cancer cells 
(Figure 1. f)  [
33
] and to stabilize c-Myc G-quadruplex DNA (G4-DNA) by affecting its 
conformation [
34
]. Interestingly, Ru(II)-cymene complexes with intercalating ligands such as 
phen, dppz and dppn also have luminescent properties, which can be used for diagnostic 
purposes [
35
]. Contrary to the examples presented above, intercalative ligands can sometimes be 
more toxic than the corresponding Ru(II)-arene complexes bearing those ligands [
36
]. Worthy of 
note, Ru(II)-arene complexes with ligands similar to nucleic bases, namely fluorouracil 
derivatives were also reported by Hu and co-workers [
37
]. Of note, ruthenium-arene complexes 
with intercalative ligands cannot not only used to help targeting DNA but also to enable the 
loading of such compounds into micelles to enhance drug efficacy and overcome drug resistance 
[
38
]. 
Taking into account the potential of the combination of a Ru-arene complex with an 
intercalative ligand, we decided to investigate the cytotoxicity of two different DNA 
intercalating moieties, namely 11,12-dimethyldipyrido[3,2-a:2',3'-c]phenazine (Me2dppz) and 2-
(9-anthryl)-1H-imidazo[4,5-f][1,10]phenanthroline (aip), with the Ru(II)-arene scaffold (Scheme 
1.). Herein, we report on the synthesis, characterization and in-depth biological evaluation of 
three new “piano stool” ruthenium(II)-arene complexes, namely [(η6-p-
cymene)Ru(Me2dppz)Cl]PF6 (1), [(η
6
-benzene)Ru(Me2dppz)Cl]PF6 (2) and [(η
6
- p-
cymene)Ru(aip)Cl]PF6 (3).  
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Insert Figure 1 
2. Experimental 
2.1. Materials 
All chemicals were of reagent-grade quality or higher, were obtained from commercial 
suppliers and were used without further purification. Solvents were used as received or dried 
over molecular sieves. RuCl3 was purchased from I2CNS.  
2.2. Instrumentation and methods 
1
H and 
13
C NMR spectra were recorded in deuterated solvents on a Bruker DRX 400 (
1
H: 
400 MHz, 
13
C: 100.6 MHz), Bruker Ultrashield Advance III spectrometer 500 (
1
H: 500 MHz, 
13
C: 126 MHz) or Varian Gemini-200 (
1
H: 200 MHz, 
13
C: 50 MHz) MHz spectrometers at room 
temperature. The chemical shifts, δ, are reported in ppm (parts per million), and coupling 
constants (J) in Hertz. The residual solvent peaks have been used as an internal reference. The 
abbreviations for the peak multiplicities are as follows: s (singlet), d (doublet), dd (doublet of 
doublets), t (triplet), q (quartet), m (multiplet), and br (broad). ESI mass spectra were recorded 
on a Bruker Esquire 6000 spectrometer. Elemental microanalyses were performed on a 
LecoCHNS-932 elemental analyzer. Infrared spectra were recorded on a Nicolet 6700 FT-IR 
spectrometer using the ATR technique. Conductivity measurements were performed using a 
Crison MultiMeter MM41 instrument. 
2.3. Synthesis 
The ligand 11,12-dimethyldipyrido[3,2-a:2',3'-c]phenazine (Me2dppz) was synthesized by 
condensation of 1,10-phenathroline-5,6-dione [
39
] with 4,5-dimethylbenzene-1,2-diamine 
according to a published procedure [
40
, 
41
]. The ligand2-(9-anthryl)-1H-imidazo[4,5-f][1,10] 
phenanthroline (aip) was prepared by condensation of the same dione with 9-anthraldehyde 
under conditions described in the literature [
42
].  The ruthenium dimers [(η6-p-cymene)-RuCl2]2 
and [(η6-benzene)-RuCl2]2 were prepared according to a published procedure [
43
].  
[Ru(η6-p-cymene)(Me2dppz)Cl]PF6 (1) 
Me2dppz (36 mg, 0.116 mmol) was dissolved in 5 mL of methanol and 5 mL of 
dichloromethane. To this solution, a solution of [(η6-p-cymene)-RuCl2]2 (35.5 mg, 0.058 mmol) 
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in 4 mL of dichloromethane was then added dropwise with constant stirring. The mixture was 
stirred at room temperature for 5 h and then filtered. NH4PF6 (28 mg, 0.174 mmol) was then 
added to the solution and left to stir over night at room temperature. The yellow precipitate, 
which formed, was filtered and washed with cold Et2O, MeOH and dried in vacuo. Yield: 56.6 
mg (64 %). 
Elemental analysis: Calcd. for C30H28ClF6N4PRu x 2H2O C, 47.28; H, 4.23; N, 7.35. Found: C, 
47.44; H, 3.83; N, 7.51. IR (cm
-1
): 3648 (w), 3091 (w), 2971 (w), 1493 (w), 1471 (w), 1411 (w), 
1359 (w), 840 (s), 729 (w), 558 (w). 
1
H NMR (400 MHz, DMSO-d6) δ 10.00 (d, J = 4.8 Hz, 2H), 
9.55 (d, J = 8.0 Hz, 2H), 8.28 (dd, J = 7.6, 5.2 Hz, 2H), 8.10 (s, 2H), 6.40 (d, J = 6.0 Hz, 2H), 
6.17 (d, J = 6.0 Hz, 2H), 2.71 (m, 1H), 2.59 (s, 6H), 2.24 (s, 3H), 1.01 (d, J = 6.8 Hz, 6H). 
13
C 
NMR (100 MHz, DMSO-d6) δ 157.00, 147.54, 143.93, 141.04, 138.07, 134.93, 129.41, 127.69, 
127.46, 104.78, 102.64, 85.91, 84.22, 30.43, 21.74, 20.18, 18.21. ESI-MS (CH3CN): m/z 581.2 
([M-PF6]
+
). 
[Ru(η6-benzene)(Me2dppz)Cl]PF6 (2) 
To a solution of Me2dppz (35 mg, 0.113 mmol) in 8 mL of dichloromethane was added a 
suspension of [(η6-benzene)-RuCl2]2 (28 mg, 0.056 mmol) in 6 mL of methanol. The reaction 
mixture was stirred for 5 h at room temperature and filtered. NH4PF6 (27 mg, 0.168 mmol) was 
then added to the solution. The solution was then left to stir over night. The pale yellow 
precipitate, which formed, was filtered, washed with cold Et2O, MeOH and dried in vacuo. 
Yield: 56.7 mg (73 %). 
Elemental analysis: Calcd. For C26H20ClF6N4PRu x H2O C, 45.39; H, 3.22; N, 8.14. Found: C, 
45.35; H, 3.061; N, 8.162. IR (cm
-1
): 3097 (w), 2988 (w), 2942 (w), 1497 (w), 1442 (w), 1411 
(w), 1356 (w), 833 (s), 731 (w), 556 (w).  
1
H NMR (500 MHz, DMSO-d6) δ 10.08 (dd, J = 5.5, 
0.8 Hz, 1H), 9.54 (dd, J = 8.0, 1.0 Hz, 1H), 8.26 (dd, J = 6.8, 2.5, Hz, 1H), 8.09 (s, 1H), 6.39 (s, 
6H), 2.58 (s, 6H). 
13
C NMR (125 MHz, DMSO-d6) δ 157.31, 147.59, 144.00, 141.08, 137.90, 
134.99, 129.36, 128.30, 127.71, 127.31, 86.87, 20.18. ESI-MS (CH3CN): m/z 525.1 ([M-PF6]
+
). 
[Ru(η6-p-cymene)(aip)Cl]PF6 (3) 
To a suspension of 2-(9-anthryl)-1H-imidazo[4,5-f][1,10]phenanthroline (aip) (30 mg, 0.075 
mmol) in 5 mL of dichloromethane and 5 mL of methanol was added dropwise a solution of [(η6-
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p-cymene)-RuCl2]2 (23 mg, 0.038 mmol) in 5 mL of dichloromethane. The reaction mixture was 
stirred for 8 h at room temperature and then filtered. NH4PF6 (24.2 mg, 0.15 mmol) was then 
added to the solution. The solution was then left to stir for 2 h. The pale yellow precipitate, 
which formed, was filtered, washed with cold Et2O and MeOH and dried in vacuo. Yield: 60.4 
mg (94 %). 
Elemental analysis: Calcd. For C37H34ClF6N4O2PRu x 2H2O C, 52.39; H, 4.04; N, 6.61. Found: 
C, 51.85; H, 4.08; N, 6.64. IR (cm
-1
): 3640 (w), 3060 (m), 2970 (m), 2930 (m), 1607 (w), 1544 
(w), 1507 (w), 1447 (w), 1413 (w), 1365 (w), 839 (s), 742 (m), 556 (w). 
1
H NMR (500 MHz, 
DMSO-d6) δ 14.83 (bs, 1H), 9.92 (d, J = 5.0 Hz, 2H), 9.19 (bs, 2H), 8.95 (s, 1H), 8.30 – 8.20 
(m, 4H), 7.80 (d, J = 8.0 Hz, 2H), 7.61 (t, J = 7.0 Hz, 2H), 7.53 (s, 2H), 6.3 9 (d, J = 6.5 Hz, 2H), 
6.15 (d, J = 6.0 Hz, 2H), 2.67 (m, 1H), 2.25 (s, 3H), 0.96 (d, J = 7.0 Hz, 6H).
13
C NMR (125 
MHz, DMSO-d6) δ 153.92, 150.66, 143.31, 132.44, 130.82, 130.64, 129.61, 128.64, 127.31, 
126.39, 125.83, 125.49, 124.40, 104.02, 103.10, 86.23, 83.97, 30.46, 21.73, 18.33. ESI-MS 
(CH3CN): m/z 667.2 ([M-PF6]
+
). 
2.4. Bioassays 
For the biological examination (intracellular accumulation, interactions with DNA, 
cytotoxicity), the complexes and corresponding ligands were dissolved in DMSO (20 mM) prior 
to use. DMSO solutions were mixed with the aqueous solutions used in biological studies 
immediately prior to use, so that the final concentration of DMSO never exceeded 0.1% (v/v). 
2.5. Cell culture 
Three human tumor cell lines: human cervix adenocarcinoma (HeLa), human alveolar 
basal adenocarcinoma (A549), human breast adenocarcinoma (MDA-MB-231), and one non-
tumor human lung fibroblast cell line (MRC-5), were maintained as monolayer culture in 
nutrient medium, (Roswell Park Memorial Institute) RPMI-1640 (Gibco). RPMI-1640 medium 
was supplemented with 5% fetal calf serum (FCS, Gibco), 100 U mL
-1
 penicillin and 100 mg 
mL
-1
 streptomycin, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (25 mM), L-
glutamine (3 mM). The cells were grown at 37 °C, in 5% CO2 and humidified air atmosphere. 
2.6. Trypan blue exclusion assay 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
8 
 
Trypan blue (TB) exclusion assay was used to determine the number of viable cells 
present in a cell suspension. TB test is based on the principle that viable cells possess intact cell 
membranes that exclude trypan blue dye, whereas non-viable cells do not. Staining was carried 
out following a previously described protocol [
44
]. Briefly, cell suspension (50 µL) was mixed 
with 250 µL of filtered TB solution (0.4%). Immediately after, cells were visually examined by 
light microscopy and cell number determined using a Neubauer chamber. Viable cells appear 
with clear cytoplasm, while non-viable appear with blue cytoplasm. 
2.7. Cytotoxicity studies 
The cytotoxicity of the compounds towards lung (A549), breast mammary gland (MDA-
MB-231), cervix (HeLa) cancer cell lines and Normal Human Lung cells (MRC5) was measured 
by a fluorometric cell viability assay using resazurin (Promocell GmbH). Cells were plated in 
triplicates in 96-well plates at a density of ~5 x 10
3
 cells/well in 100 μL 24 h prior to treatment. 
Cells were then treated with increasing concentrations of compounds for 48 h. After 48 h in the 
incubator, the medium was replaced by 100 μL medium containing resazurin (0.2 mg/mL final 
concentration). After 4 h of incubation at 37 °C, the fluorescence of the highly red fluorescent 
resorufin product was quantified at 590 nm emission with 540 nm excitation wavelength in a 
SpectraMax M5 microplate Reader. 
2.8. Flow-cytometric analysis of cell cycle phase distribution 
Quantitative analysis of cell cycle phase distribution was performed by flow-cytometric 
analysis of the DNA content in fixed HeLa cells, after staining with propidium iodide (PI) [
45
]. 
Cells were seeded at density of 2 x 10
5
 cells per well, into 6-well plates (Thermo Scientific 
Nunc™), in 2 mL of nutrition medium. Cells were continually exposed to the investigated 
ruthenium complex 1 or CDDP at concentrations corresponding to IC50 and 2 x IC50. Control 
cells were incubated only in nutrient medium. After 24 h or 48 h of growth, cells were collected, 
washed twice with ice-cold phosphate-buffered saline (PBS), and fixed overnight, in 70% 
ethanol. After fixation, cells were washed with PBS, and incubated with RNaseA (1 mg/mL) for 
30 min, at 37 C. Immediately before flow-cytometric analysis, cells were stained with PI, at a 
concentration of 400 mg/mL. Cell cycle phase distribution was investigated using fluorescence 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
9 
 
activated cell sorter (FACS), by Calibur Becton Dickinson flow cytometer, at 488 nm excitation 
line (Argon-ion laser). Collected data were analyzed by Cell Quest computer software. 
2.9. Flow-cytometric analysis of apoptosis by Annexin-FITC  
Quantitative analysis of apoptotic and necrotic cell death induced by complex 1, was 
performed by Annexin-FITC (fluorescein isothiocyanate) apoptosis detection kit, according to 
the manufacturer's instructions (BD Biosciences). HeLa cells (2 x10
5
) were seeded into 6-well 
plates (Thermo Scientific Nunc™), in 2 mL of RPMI medium. After 24 h of growth, cells were 
treated with complex 1 or CDDP, for 24 h and 48 h, at concentrations corresponding to their IC50 
and 2 x IC50 values. Following treatment, cells were washed twice with ice-cold PBS and then 
resuspended in 200 µl binding buffer (10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, 2.5 mM 
CaCl2). 100 µl of cell suspension (10
5
 cells) was transferred to a 5 mL culture tube and mixed 
with 5 µl of Annexin-FITC and 5 µl of propidium iodide (PI) [
46
]. Cells were vortexed and 
incubated for 15 min, at 25 °C in the dark. Afterwards, 400 µl of binding buffer was added to 
each tube and analyzed using a FACS Calibur Becton Dickinson flow cytometer and Cell Quest 
computer software. 
2.10. Morphological analysis of cell death by fluorescent microscopy 
HeLa cells (2 x 10
4
) were seeded into 6-well plates (ThermoScientific Nunc™) in 2 mL 
of nutrient medium. After 24 h of growth, cells were exposed to complex 1 or CDDP, at IC50 or 2 
x IC50 concentrations. Following 24 h or 48 h of treatment, cells were stained with ethidium 
bromide (5 µg/mL) and acridine orange (1.5 µg/mL), according to standard procedure [
47
], and 
immediately after, observed under the fluorescent microscope Axio Observer Z1, using 
AxioVision imaging software (Carl Zeiss MicroImaging GmbH). 
2.11. Sample microwave digestion for ICP-MS 
The digestion was performed on an Advanced Microwave Digestion System (ETHOS 1, 
Milestone, Italy) using HPR-1000/10S high pressure segmented rotor. The pressure-resistant 
PTFE vessels (volume 100 mL), which were used in this study, consisted of fluoropolymer liner. 
Before use, the PTFE vessels were acid cleaned and rinsed with ultra-pure water. This type of 
vessel permits a maximum temperature of 240 ºC and a maximum pressure of 100 bar. 
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Maximally, 10 PTFE vessels could simultaneously be mounted on the rotor. The internal 
temperature was monitored only with one vessel equipped with a sensor unit. Temperature 
sensor is over a sensor-protecting tube directly contacted with digested solution. The entire 
sample was precisely and quantitatively transferred, mixed in each clean vessel with 3 mL of 
HNO3 (65%), 4 mL of ultra-pure water and 2 mL of H2O2 (30%) (Suprapure®, Merck, 
Germany) and then heated with microwave energy for 10 min. The temperature was controlled 
with a predetermined power program. The temperature was typically raised to 200 ºC in the first 
10 min, and to a peak temperature of 200 ºC in the next 10 min, and then cooled down rapidly. 
After cooling and without filtration, the solution was diluted to a fixed volume into a 10 mL 
volumetric flask and made up to 10 mL volume with ultra-pure water. Ultra-pure water was 
prepared by passing doubly deionized water from Milli-Q system (Millipore, Bedford, MA, 
USA) to a resistivity of 18.2 MΩ·cm. 
2.12. Measurement of intracellular ruthenium(II) and platinum(II) accumulation using ICP-MS 
 Intracellular accumulation of complex 1 was analyzed in HeLa cells, in comparison to 
CDDP, using inductively coupled plasma mass spectrometry (ICP-MS), using a Thermo 
Scientific iCAP Qc ICP-MS (Thermo Scientific, Bremen, Germany) [
48
] spectrometer with 
operational software Qtegra. The instrument was optimized for optimum performance in He 
KED (Kinetic Energy Discrimination) mode using the supplied autotune protocols. The ICP-MS 
instrument was tuned using a solution TUNE B iCAP Q (1 µg/L of each: Ba, Bi, Ce, Co, In, Li, 
U) provided by the manufacturer Thermo Scientific, Germany. External standards for the 
instrument calibration was prepared on the basis of ruthenium, plasma standard solution, 
Specpure®, Ru 1000µg/mL certified reference solution ICP Standard purchased from Alfa Aesar 
GmbH & Co KG (Germany). The acid concentration of the external standards was carefully 
matched to the acid concentration of the prepared samples. Two types of blanks are required for 
the analysis of the samples prepared. The calibration blank is used in establishing the analytical 
curve and the method blank is used to identify possible contamination resulting from either the 
reagents (acids) or the equipment used during sample processing. For cellular uptake 
experiments, the limit of quantitation (LOQ) for platinum was determined to be 34 ng/L and 88 
ng/L for ruthenium. HeLa cells (1 x 10
6
) were seeded into 75 cm
2
 dishes (Thermo Scientific 
Nunc™), and at the exponential phase of growth, cells were treated with complex 1 or CDDP at 
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equimolar concentrations of 10 M. Following 4 h and 20 h of continuous treatment, attached 
cells were harvested by scraping, washed by ice cold PBS and cell pellet was collected by 
centrifugation at 2000 rpm, 10 min. Due to the considerable detachment of treated cells (> 90%), 
following 20 h complex 1 incubation, detached cells were also collected for examination of 
Ru(II)/Pt(II) total intracellular accumulation and DNA-binding. 
For verification measurements of Ru and Pt on ICP-MS were made two sets of controls 
(intracellular and DNA). On each pair of control, and complex Pt and Ru is spiked, respectively. 
As for the samples, after total mineralization and the dilution in the volumetric flask to 10 mL, 
the expected concentration in the solution of Pt was 0.100 mg/L, and Ru was 0.200 mg/L. 
Recovery rate for Pt was 101 ± 3%, and for 98 ± 4% of Ru.  
 
2.13. Sample preparation for the measurement of DNA-binding using ICP-MS 
Binding of C1 to cellular DNA was analyzed in HeLa cells, using inductively coupled 
plasma mass spectrometry (ICP-MS). HeLa cells were prepared and cell pellet collected using 
the same procedure as described above [
49
, 
50
]. Total DNA was isolated using TRI Reagent® 
(Sigma Aldrich), according to the manufacturer's procedure and concentrations were determined 
spectrophotometrically by measuring absorbances (Eppendorf BioPhotometer 6131). 
3. Results and Discussion  
3.1. Synthesis and characterization of the complexes 
 All complexes were synthesized following the synthetic routes described in Scheme 1.  
The resulting complexes were found to be soluble in DMSO and DMF and to be partially soluble 
in methanol and acetone. All complexes were characterized by 
1
H and 
13
C NMR, IR, elemental 
analysis and mass spectrometry. 
 In the 
1
H and 
13
C NMR spectra of the complexes, all protons and carbons appear at 
chemical shifts expected for such types of compounds. Importantly, as determined by the 
integrals of the 
1
H NMR spectra, the arene to Me2dppz/aip ratio was found to be 1:1. This 
suggests a piano-stool geometry for the complexes with a coordinated chloride ligand. This 
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assumption is confirmed by analysis of the ESI-MS spectra, where a single peak for the products 
was detected corresponding to the complexes without a counterion PF6
−
.  
Insert Scheme 1 
3.2. Stability of the complexes in DMSO 
Since all complexes were found to be well soluble in DMSO, stock solutions for IC50 
were prepared in this solvent. In these experimental conditions, the chloride ligand of the Ru(II) 
arene complexes could undergo a ligand exchange with the DMSO molecule leading potentially 
to problems during the IC50 value determination [
51
]. For this reason, we first explored the 
stability of all complexes in DMSO-d6 solutions using 
1
H NMR spectroscopy. We followed the 
changes in the spectra of the complexes over 48 h. The signals of the ligand did not change over 
time, and this for all complexes. This observation clearly indicates that the complexes are stable 
in DMSO. 
3.3. Conductivity measurements 
To further confirm that the complexes are stable over time in DMSO, conductivity 
measurements were carried out immediately after dissolution in DMSO and after 24 h. The 
conductivity values were unchanged after 24 h, and suggested existence of one cation and one 
anion, or 1:1 type electrolyte, by literature data [
52
]. Conductivity values for 1 mM solutions of 
complexes 1, 2 and 3 were 40.5, 36.6 and 35.5 Ω-1 cm2 mol-1, respectively.   
3.4. Resazurin assay  
The cytotoxicity of the three new complexes 1-3 as well as of the free ligands was studied 
in three human cancer cell lines, namely human lung carcinoma (A549), human mammary gland 
breast adenocarcinoma (MDA-MB-231), human cervix adenocarcinoma (HeLa) and in one non-
tumor human fetal lung fibroblast cell line (MRC-5). The starting ruthenium(II)-dimers and the 
well-known chemotherapeutic agent cisplatin were also tested as reference compounds. As 
shown in Table 1, all starting compounds (dimers and ligands) were found to be non-toxic in all 
cell lines studied in this work. Interestingly, a similar behavior was observed for complex 2. This 
observation is in agreement with a previous report describing the cytotoxicity of ruthenium 
complexes containing different η6-arene ligands [53]. On the contrary, complexes 1 and 3, which 
contain both the p-cymene ligand, were found to be extremely toxic against all tested cells. 
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Importantly, these two complexes were found to be more cytotoxic than cisplatin. Of note, 
ruthenium-arene complexes with carbene ligands complexes were found to be also extremely 
active against cancer cells although they were not containing any intercalating ligands [
54
]. 
Nonetheless, since complex 1 was found to be the most cytotoxic complex of the series studied 
in this work, it was used for all following biological studies presented below. Of note, HeLa cells 
were chosen for all further biological studies since they showed the highest sensitivity to the 
action of complex 1 (IC50=0.6 ± 0.5). It has to be noted that the chloride ligand in complex 1 may 
rapidly hydrolyse and generate an aqua complex. This mechanism is usually considered as the 
necessary step prior to reaction of complex with biological targets in cell [
55
, 
56
].   
Insert Table 1 
3.5. Cell cycle analysis  
To investigate whether complex 1 interferes with cell cycle progression, flow cytometry 
analysis of cell cycle phase distribution was examined in HeLa cells using propidium iodide (PI) 
staining. The effects of complex 1 and cisplatin were analyzed at two concentrations (IC50 and 2 
x IC50) and two time points (24 h and 48 h). The results are presented in Figure 2. Following 24 h 
incubation, complex 1 caused changes characterized by gradual loss of cells in the G1 phase and 
accumulation of cells in the G2-M phase. After prolonged treatment (48 h) complex 1 caused 
delay in the S phase of the cell cycle, observed in a concentration dependent manner, 17.1% and 
21 %, at IC50 and 2 x IC50, respectively, compared to the control (12.9 %). Subsequently, there 
was accumulation of cells in the sub-G1 fraction, which increased with concentration, up to 
24.5% (at 2 x IC50) (Figure 2), and was higher than that caused by cisplatin (16.4%). The 
generation of a sub-G1 peak is considered as a hallmark of cleaved DNA in cells that underwent 
cell death [
57
, 
58
]. Polypyridyl aromatic derivatives and their metal complexes have been 
extensively described in literature as strong DNA intercalators [Error! Bookmark not defined., 
Error! Bookmark not defined.]. However, ruthenium complexes carrying polypyridyl-ligands 
may catalyze DNA cleavage by means of different mechanisms, including direct binding and 
conformational distortion, by topoisomerase inhibition, indirectly by reactive oxygen species 
(ROS) induction, or by photocleavage [
59
, 
60
, 
61
, 
62
, 
63
]. Increase of sub-G1 DNA-content caused 
by cisplatin represents apoptotic DNA fragmentation. This observation is in agreement with 
established literature on the mechanism of action of CDDP [
64
, 
65
, 
66
]. Internucleosomal-DNA 
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fragmentation appeared in the course of apoptotic cell death, triggered by non-reparable 
cisplatin-DNA adducts. The changes in the cell cycle caused by complex 1 strongly suggest that 
direct DNA binding of complex 1 occurred in a concentration- and time-dependent manner. 
These results are in agreement with previous literature reports on the ruthenium compounds 
carrying dipyridophenazine (dppz) derivative, which were shown to act as strong cytotoxic and 
DNA binding agents [
67
]. 
Insert Figure 2 
3.6. Results of Annexin-FITC apoptosis assay 
The potential of complex 1 or cisplatin to induce apoptosis in HeLa cells was analyzed 
by flow cytometry and Annexin-FITC/propidium iodide staining. The data obtained are 
presented in Figure 3 as a percentage of early apoptotic cells [FITC(+)PI(-)], necrotic cells 
[FITC(+)/PI(+)] and dead cells [FITC(-)/PI(+)]. The results show that complex 1 did not initiate 
phosphatidylserine externalization, which is a characteristic of apoptotic changes since  
(FITC+PI-) staining had a level comparable to the control at both 24 h and 48 h of drug 
incubation. Under the same treatment conditions, cisplatin, which was used as reference 
compound, caused increase of FITC(+)PI(-) staining (early apoptosis), up to 22.6% (24 h)  and 
10.8% (48 h). Necrotic changes, FITC(+)/PI(+), following complex 1 action were not observed 
and were at levels comparable to the control.  
Insert Figure 3 
3.7. Results of morphological analysis of cell death 
Fluorescent microscopy and acridine orange/ethidium bromide (AO/EB) staining were 
used to analyze morphological characteristics of cell death [
68
]. Microphotographs of HeLa cells 
stained by AO/EB, following 48 h treatment with complex 1 or cisplatin, are presented in Figure 
4. Non-treated cells (control cells) are dense, light green colored and elongated with spindle-
shape. Only after prolonged treatment (48 h), with lower concentration (IC50) of complex 1, 
certain morphological changes appeared. Namely, cells started to lose their normal morphology 
and became rounded, reduced in size, with condensed and eccentrically located nuclei and with 
still intact cell membrane, since cells incorporated only AO (green fluorescence). At a higher 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
15 
 
concentration of complex 1 (2 × IC50), the number of cells was markedly reduced compared to 
the control as many of them detached. Among the cells attached, we observed some with 
necrotic morphology (i.e. cells were orange-colored due to disrupted cell membrane). Switch 
from apoptosis to cell death morphologies with necrotic features was previously described in 
literature [Error! Bookmark not defined., 
69
, 
70
] as onset of necrotic cell changes may result 
from a variety of stimuli, including inactivation of certain enzymes, cell energy deprivation 
(ATP decrease), or ligand binding to specific plasma membrane receptors. Additional studies 
will however be necessary to precisely address the mechanism of cytotoxic action of complex 1. 
Insert Figure 4 
 
3.8. ICP-MS measurement of intracellular accumulation  
One of the major goals in the development of novel metal-based anticancer drug 
candidates is to obtain an efficient uptake of the metal into tumor cells, thereby increasing 
therapeutic efficacy and decreasing toxicity for healthy tissue. In order to assess how efficiently 
complex 1 was taken up by HeLa cells, we used inductively coupled plasma mass spectrometry 
(ICP-MS) [
71
]. Importantly, we compared this uptake with cisplatin (CDDP). Figure 5 
summarizes the intracellular content (ng metal/10
6
 cells) following 4 h or 20 h treatment, with 
equimolar concentrations, 10 M, of complex 1 and CDDP. Cell viability and number were 
determined by tripan blue assay.  Measurements, following 20 h of complex 1 action, were 
performed in the adherent cells (5.6%) and cells detached from surface, which represented more 
than 90 % of the assayed sample. At the same treatment conditions, cisplatin did not cause cell 
detachment in a significantly higher level compared to the control. It should be noted that 
changes in HeLa cells viability, that occurred 20 h after administration of complex 1 (10 µM), 
were characterized by significant cell detachment, which is also characteristics of cells dying by 
apoptosis [
72
, 
73
]. Moreover, as already described in literature [
74
, Error! Bookmark not 
defined.] biological action of ruthenium (II) complexes carrying large and rigid aromatic ligands 
such as dipyridophenazine (dppz), may involve interactions with cell membranes, with 
consequent modification of cell membrane function and cell adhesion properties. Thus, in order 
to obtain complete data of distribution of ruthenium complex 1 in HeLa cells, we considered that 
both adherent viable cells, TP(-), and detached cells, TP(+), should be analyzed by ICP-MS. As 
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can be seen Figure 5, the total ruthenium accumulation increased in a time- and concentration-
dependent manner. Importantly in the context of anticancer drug research, complex 1 
accumulated in cells more efficiently than cisplatin. Uptake of complex 1 (ng Ru/10
6
 cells) 
following short-term treatment (4 h), 110.5 ± 0.8, was approximately 17-fold higher than 
cisplatin uptake (6.5 ± 0.1 ng Pt/10
6
 cells). After 20 h incubation, the accumulation rate of 
complex 1 (ng Ru/10
6
 cells), in detached cells, 175.6 ± 0.8, exceeded the one of cisplatin (8 ± 0.1 
ng Pt/10
6
 cells) by approximately 20-fold. However, complex 1 concentration in the adherent 
cells, 85.4 ± 1.1 ng Ru/10
6
 cells, seemed to decrease over time. This observation could be 
explained if cell division took place, in this small percentage (5.6%) of treated cells, even though 
they were under strong cytotoxic stress.  
All in all, these results clearly indicate an enhanced pattern of cellular uptake in HeLa 
cells of complex 1 compared to cisplatin. The lipophilic characteristics of aromatic ligands such 
as dipyridophenazine (dppz) certainly facilitate influx of the ruthenium(II) complex through cell 
membrane by passive diffusion [
75
]. However, as reported previously [
76
], this increase in 
lipophilicity may contribute to adverse biological effects such as toxicity or reduced selectivity 
toward cancer cells. The present study confirms that the coordination of the biologically inactive 
dipyridophenazine derivative (Me2dppz) to a Ru(II)-p-cymene unit results in a complex with an 
enhanced cellular uptake and cytotoxicity compared to cisplatin. 
Insert Figure 5 
 
3.9. ICP-MS measurement of DNA binding 
It is well-documented that the Pt(II) drugs have a mode of cytotoxic action related to 
DNA binding [Error! Bookmark not defined.]. Ruthenium complexes might interact with 
DNA directly [
77
, 
78
], or may damage DNA indirectly, through induction of mitochondrial-
apoptotic cell death or oxidative stress [
79
, 
80
].
 
In order to assess the ability of complex 1 to bind 
to DNA in HeLa cells, the amount of ruthenium bound to DNA was determined by ICP-MS 
following 4 h and 20 h treatment. Following prolonged action of complex 1 (20 h), 
measurements were performed in cells attached and cells detached, as described above. For this 
purpose, cells were collected immediately after treatment, and nuclear DNA was isolated and 
quantified. Stock solutions of DNA gave a ratio of UV absorbance A260/A280 in the range of 
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2.05-2.08. The results of this ICP-MS study (Figure 5) show that complex 1 binds to cellular 
DNA more efficiently than CDDP. The level of complex 1 binding to DNA observed after 4 h 
incubation, 96.4 ± 4.2 (pg Ru/ug DNA), was much higher than DNA-platination, 16.7 ± 0.1 (pg 
Pt/ug DNA). With time extension, cisplatin DNA-binding increased slower than complex 1 
DNA-binding. Indeed, after 20 h of incubation, the ruthenium DNA-content (pg Ru/ug DNA) 
measured in both cells fractions: 358.3 ± 4.6 (attached); 407.3 ± 7.7 (detached), exceeded that of 
cisplatin 38.4 ± 0.5 by approximately 10-fold. We may suggest that lipophilic character of 
complex 1 facilitates transport through the cell membrane. Once inside the cell, complex 1 enters 
the nucleus efficiently and reacts with nuclear DNA. ICP-MS measurement showed that 
ruthenium-DNA binding was comparably high in both adherent cells (TP-), and detached cells 
(TP+). Further study would be necessary to precisely determine if complex 1, particularly at the 
high concentrations (10 µM), may also stay attached to the cell membrane and interfere to cell 
adhesion.  
All in all, these ICP-MS results on DNA binding are in agreement with the intracellular 
accumulation study and the cytotoxicity data. Complex 1 enters cell faster and targets nuclear 
DNA more efficiently than cisplatin. This observation could be explained by controlled ligand 
dissociation kinetics. According to Sadler and Dyson [Error! Bookmark not defined., 
81
, 
82
], 
complexes of the type [Ru(η6-p-cymene)(L)Cl]+ are activated to the cationic species [Ru(η6-p-
cymene)(L)H2O]
2+
, via substitution of the chloride ligand with water. [Ru(η6-p-cymene)(L)]2+ 
can then bind to DNA and other nucleophilic targets in the cell. In addition, we suggest that the 
hydrophobic/stacking interaction of the planar aromatic Me2dppz moiety with nucleobases in 
DNA-helix, and the hydrophobic interaction provided by the p-cymene ligand, may 
synergistically contribute to the enhanced DNA binding affinity of the Ru(II)-arene complex 
cation [Ru(η6-p-cymene)(L)Cl]2+  compared to cisplatin [Error! Bookmark not defined., 
Error! Bookmark not defined.].  
4. Conclusion 
In the present study, half-sandwich Ru(II)-arene complexes of the type  [(η6-p-
cymene)Ru(Me2dppz)Cl]PF6 (1), [(η
6
-benzene)Ru(Me2dppz)Cl]PF6 (2) and [(η
6
-p-
cymene)Ru(aip)Cl]PF6 (3), have been synthesized and characterized in-depth using different 
analytical methods. Cytotoxic activity studies on three human tumor cell lines, and one non-
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tumor in vitro cell model (MRC-5) revealed that the complexes carrying p-cymene as an arene, 
namely 1 and 3, had a significantly higher cytotoxic activity than cisplatin, particularly in 
cervical (HeLa) and breast (MDA-MB-231) cancer cells. On the contrary, the corresponding 
ligands did not have any cytotoxic effects (IC50 > 100 M). Biological studies to unveil the 
mechanism of action of complex 1 revealed that this compound acts as strong a cytotoxic agent 
due to an efficient cellular accumulation and its ability to reach and bind nuclear DNA with a 
much higher affinity than cisplatin. Indeed, ICP-MS measurements showed that the cellular 
uptake and nuclear DNA binding of complex 1 after 4 h incubation were roughly 17- and 6- fold, 
respectively, higher than those of cisplatin. FACS analysis additionally indicated the ability of 
complex 1 to obstruct cell cycle progression in a concentration- and time-dependent manner, 
causing arrest in the G2-M and S phases, followed by the generation of considerable Sub-G1 
DNA content (up to 24.5 % at 2 x IC50, 48 h), as a hallmark of fragmented DNA. ICP-MS 
experiments also revealed that facile transport of the complex cation across the cell membrane, 
may be accounted to the hydrophobicity of both p-cymene and the planar aromatic Me2dppz 
ligand, which, synergistically, may contribute to the DNA binding of complex 1. For metal 
complexes carrying polypyridyl ligand such as dppz (complex 1) in the present study, a DNA-
based cytotoxicity may be anticipated [Error! Bookmark not defined., 
83
]. Organic agents that 
strongly bind DNA due to intercalation are extremely successful anticancer agents. Currently, 
there are several drugs (i.e Daunorubicin [
84
, 
85
, 
86
], Doxorubicin [Error! Bookmark not 
defined., 
87
, 
88
, 
89
] and Amsacrine [
90
, 
91
, 
92
, 
93
]), which are approved by the FDA for the 
treatment of human cancers, although with a limited range of effectiveness. In a similar line of 
thoughts, half-sandwich Ru(II) complexes with benzene or p-cymene as the arene ligand and N-
methylhomopiperazine or N-methylhomopiperazine as the anthracenyl moiety were found to 
have an enhanced intercalation and cytotoxicity properties if the intercalative ligand possess an 
extended aromaticity [
94
]. Enhanced DNA binding of the Ru(II) compounds of the type [Ru(η6-p-
cymene)(L)Cl] 
2+
 where L is a DNA intercalating ligand such as dipyridophenazine derivative 
(Me2dppz), may help the development of a new family of specific DNA-targeting agents. 
However, as shown in this study, this strong DNA targeting can go on the expense of cancer cell 
selectivity. Further structure-activity study in our laboratories will be directed toward obtaining 
complexes with a higher selectivity. 
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 Figure 1. Examples of organometallic ruthenium complexes bearing an intercalating moiety. 
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Figure 2. Diagrams presenting cell cycle phase distribution of HeLa cells, treated with complex 
1 or CDDP. These results were obtained by flow-cytometric analysis of DNA content in fixed 
cells, after staining with PI. HeLa cells were collected following 24 or 48 h treatment, with 
complex 1 or CDDP, at concentrations corresponding to IC50 and 2 x IC50. Bar graphs show 
representative measurements of at least three independent experiments. 
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Figure 3. Diagrams show results of dual PI/Annexin V-FITC staining, (abbreviated as P/A), 
monitored by FACS-flow in HeLa cells, following 24 h and 48 h treatment with  complex 1 or 
CDDP at concentrations corresponding to IC50  and 2 x IC50. Bar graphs present the percentage 
of live cells PI(-)/FITC(-); early apoptotic cells at lower-right quadrant, PI(-)/FITC(+); necrotic 
cells at upper-right quadrant, PI(+)/FITC(+); and dead cells at upper-left quadrant, PI(+)/FITC(-
). Bar graphs represent measurements of one of at least three independent experiments. 
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Figure 4. Fluorescent micrographs presenting HeLa cells treated with complex 1 for 48 h at 
concentrations corresponding to A) IC50 and B) 2 x IC50. C) Untreated HeLa cells were used as 
negative control; D) HeLa cells treated with CDDP at IC50, used as positive control for apoptotic 
morphological changes. Cell staining by Ethidium bromide (EB) and Acridine orange (AO) was 
analyzed using a fluorescent microscope Axio Observer Z1, using AxioVision imaging software 
(Carl Zeiss MicroImaging GmbH) was used. AO is a vital dye, which stains both live and dead 
cells. EB only stains cells that have lost membrane integrity. Untreated control cells appeared 
uniformly green with spindle-shape.  
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Figure 5. Results of ICP-MS analysis of complex 1-ruthenium(II) and cisplatin-platinum(II) 
intracellular accumulation and DNA binding, in HeLa cells, after 4 and 20 h treatment, with 10 
M of the compounds. A) cisplatin intracellular accumulation (ng Pt(II)/106cells); B) complex 1 
intracellular accumulation (ng Ru(II)/10
6
cells);  C) cisplatin-DNA binding (pg Pt(II)/g DNA); 
D) complex 1-DNA binding (pg Ru(II)/gDNA) a) adherent cells, TP(-) after complex 1 action 
(20 h); d) cells detached, TP(-)  after complex 1 action (20 h); Bar graphs represent mean ± SD 
of three independent measurements. 
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Scheme 1. Synthesis of complexes 1- 3. 
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Table 1. IC50 values of complexes 1-3 and of the starting ruthenium(II) dimers and ligands as 
well as cisplatin against different human cell lines  
Compounds 
IC50 Values (µM) 
A549 MDA-MB-231 HeLa MRC-5  
[(η6-p-
cymene)Ru(Me2dppz)Cl]
PF6 (1) 
6.9 ± 2.9 0.7 ± 0.3 0.6 ± 0.5 0.4 ± 0.1 
[(η6-
benzene)Ru(Me2dppz)Cl]
PF6 (2) 
>100 >100 >100 >100 
[(η6-p-
cymene)Ru(aip)Cl]PF6 
(3) 
24.5 ± 0.1 3.7 ± 0.3 4.9 ± 0.1 3.2 ± 0.1 
[(η6-benzene)RuCl2]2 >100 >100 >100 >100 
[(η6-p-cymene)RuCl2]2 >100 >100 >100 >100 
Me2dppz >100 58.8 >100 >100 
aip >100 >100 >100 >100 
cisplatin 28.5 ± 5.1 27.9 ± 2.7 16.4 ± 7.1 17.0 ± 6.2 
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Graphical abstract 
Three new ruthenium(II)-arene complexes, [(arene)Ru(L
1
-L
2
)Cl]PF6, where arene is benzene or 
p-cymene, and L
1
 and L
2
  are 11,12-dimethyldipyrido[3,2-a:2',3'-c]phenazine and 2-(9-anthryl)-
1H-imidazo[4,5-f][1,10] phenanthroline, have been synthesized, characterized and their 
cytotoxicity was examined. Fluorescent microscopy revealed that the most active complex 
induced both apoptotic and necrotic cell morphology characteristics.  
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Highlights 
Three new organometallic Ru(II) complexes were synthesized and characterized. 
Two complexes were highly toxic against three cancer cell lines and one non-tumor cell line. 
The mechanism of action of the most potent complex was studied. 
Intracellular accumulation and DNA binding were detected for the most potent complex.  
